Last Updated: November 13, 2026

Biogen Ma Company Profile

« Back to Dashboard

What is the competitive landscape for BIOGEN MA

BIOGEN MA has one approved drug.

There are three US patents protecting BIOGEN MA drugs.

Summary for Biogen Ma

US Patents:	3
Tradenames:	1
Ingredients:	1
NDAs:	1
Patent Litigation for Biogen Ma:	See patent lawsuits for Biogen Ma
PTAB Cases with Biogen Ma as patent owner:	See PTAB cases with Biogen Ma as patent owner

Drugs and US Patents for Biogen Ma

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biogen Ma	QALSODY	tofersen	SOLUTION;INTRATHECAL	215887-001	Apr 25, 2023		RX	Yes	Yes	10,968,453	⤷ Start Trial				⤷ Start Trial
Biogen Ma	QALSODY	tofersen	SOLUTION;INTRATHECAL	215887-001	Apr 25, 2023		RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Biogen Ma	QALSODY	tofersen	SOLUTION;INTRATHECAL	215887-001	Apr 25, 2023		RX	Yes	Yes	10,385,341	⤷ Start Trial	Y	Y		⤷ Start Trial
Biogen Ma	QALSODY	tofersen	SOLUTION;INTRATHECAL	215887-001	Apr 25, 2023		RX	Yes	Yes	10,669,546	⤷ Start Trial				⤷ Start Trial
Biogen Ma	QALSODY	tofersen	SOLUTION;INTRATHECAL	215887-001	Apr 25, 2023		RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for Biogen Ma Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Singapore	10201910844S	⤷ Start Trial
Malaysia	175665	⤷ Start Trial
Finland	C20240035	⤷ Start Trial
Poland	3757214	⤷ Start Trial
South Korea	20250113519	⤷ Start Trial
Lithuania	3126499	⤷ Start Trial
South Korea	20210097225	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Biogen Ma Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3126499	C202430041	Spain	⤷ Start Trial	PRODUCT NAME: TOFERSEN; NATIONAL AUTHORISATION NUMBER: EU/1/23/1783; DATE OF AUTHORISATION: 20240529; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1783; DATE OF FIRST AUTHORISATION IN EEA: 20240529
3126499	202440032	Slovenia	⤷ Start Trial	PRODUCT NAME: TOFERSEN; NATIONAL AUTHORISATION NUMBER: EU/1/23/1783; DATE OF NATIONAL AUTHORISATION: 20240529; AUTHORITY FOR NATIONAL AUTHORISATION: EU
3126499	24C1039	France	⤷ Start Trial	PRODUCT NAME: TOFERSEN; REGISTRATION NO/DATE: EU/1/23/1783 20240603
3126499	2490031-8	Sweden	⤷ Start Trial	PRODUCT NAME: TOFERSEN; REG. NO/DATE: EU/1/23/1783 20240603
3126499	CR 2024 00038	Denmark	⤷ Start Trial	PRODUCT NAME: TOFERSEN; REG. NO/DATE: EU/1/23/1783 20240603
3126499	PA2024531	Lithuania	⤷ Start Trial	PRODUCT NAME: TOFERSENAS; REGISTRATION NO/DATE: EU/1/23/1783 20240529
3126499	LUC00359	Luxembourg	⤷ Start Trial	PRODUCT NAME: TOFERSEN; AUTHORISATION NUMBER AND DATE: EU/1/23/1783 20240603
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.